Experimental lymphoma therapy tested in tiny early trial

NCT ID NCT05994157

Terminated Disease control Sponsor: Y-mAbs Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 1 trial tested a two-step radioimmunotherapy (CD38-SADA and 177Lu-DOTA) in patients with relapsed or refractory non-Hodgkin lymphoma. The goal was to find safe doses and dosing schedules. Only 1 participant was enrolled, and the study was terminated early, so no conclusions about effectiveness can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD38-SADA and 177Lu-DOTA (two-step radioimmunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma.
What could go wrong: This was a very early, small phase 1 trial with only 1 participant, and it was terminated early. It is unclear if the approach is safe or effective, and it may not work in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Corewell Health-BAMF Health

Grand Rapids, Michigan, 49503, United States
East Carolina University Leo W. Jenkins Cancer Center

Greenville, North Carolina, 27834, United States
HonorHealth

Scottsdale, Arizona, 85258, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Stony Brook Cancer Center

Stony Brook, New York, 11794, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.